Evidence map›Paper›PMID 42478317›Full record

ArticleBiotechnology and bioengineering2026

Highly Efficient Enzymatic Catalytic Transformation for the Synthesis of Rare Ginsenoside Compound K (CK) and Its Bioactivity Study.

Hao Tang, Shihua Han, Zidan Li, Yiwen Jiang, Meimei Fu, Zhuoyi Huang, Lei Jia, Fengrui Song, Jianguo Huang, Gloria B Kim and 2 more

Abstract read
In one paragraph

Article in Biotechnology and bioengineering, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Hao TangSuzhou Zhentai Biotechnology Co., Ltd, Kunshan Industrial Technology Research Institute, Suzhou, P. R. China.
Shihua HanDongguan Qingxi Hospital, Dongguan City, P. R. China.
Zidan LiSuzhou Zhentai Biotechnology Co., Ltd, Kunshan Industrial Technology Research Institute, Suzhou, P. R. China.
Yiwen JiangDepartment of Biomaterials and Stem Cells, Suzhou Institute of Biomedical Engineering and Technology, Chinese Academy of Science, Suzhou, P. R. China.
Meimei FuRegenerative Medicine and Tissue Repair Research Center, Huangpu Institute of Materials, Guangzhou, P. R. China.
Zhuoyi HuangRegenerative Medicine and Tissue Repair Research Center, Huangpu Institute of Materials, Guangzhou, P. R. China.
Lei JiaDepartment of Biomaterials and Stem Cells, Suzhou Institute of Biomedical Engineering and Technology, Chinese Academy of Science, Suzhou, P. R. China.
Fengrui SongSuzhou Zhentai Biotechnology Co., Ltd, Kunshan Industrial Technology Research Institute, Suzhou, P. R. China.
Jianguo HuangSuzhou Zhentai Biotechnology Co., Ltd, Kunshan Industrial Technology Research Institute, Suzhou, P. R. China.
Gloria B KimDepartment of Physiology and Biomedical Engineering, Department of Immunology, Mayo Clinic Arizona, Scottsdale, Arizona, USA.ORCID https://orcid.org/0000-0003-3772-6975
Jinshan GuoDepartment of Biomaterials and Stem Cells, Suzhou Institute of Biomedical Engineering and Technology, Chinese Academy of Science, Suzhou, P. R. China.ORCID https://orcid.org/0000-0001-8097-4902
Zhihui LuSuzhou Zhentai Biotechnology Co., Ltd, Kunshan Industrial Technology Research Institute, Suzhou, P. R. China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

As a principal metabolite of ginsenosides, compound K (CK) exhibits remarkable antioxidant, anti-inflammatory, antidiabetic, and anticancer bioactivities. However, CK is naturally scarce in ginseng and its industrial application is limited by the lack of efficient deglycosylating enzymes for large-scale CK bioproduction. Here, we report a synthetic biology-driven approach for high-yield CK production via recombinant β-glycosidase-mediated bioconversion of the polar ginsenoside Rb1. The β‑glycosidase-encoding gene was introduced into Escherichia coli BL21 (DE3), and the resulting engineered strain produced 2.1 g/L β‑glycosidase in shake flasks and 10.1 g/L in a 5-L fermentor. The crude β-glycosidase exhibited excellent enzymatic activity; at a concentration of 1.5 g/L, it converted 95% of the Rb1 substrate (initial concentration 10 g/L) to CK within 4 h. In vitro studies demonstrated CK's high cytocompatibility and potent anti-aging effects, including suppression of reactive oxygen species (via upregulation of superoxide dismutase, catalase, and glutathione peroxidase), enhanced collagen I, Ⅲ and elastin synthesis, and matrix metalloproteinase-1 inhibition. These findings highlight CK as a promising candidate for anti-wrinkle formulations, supported by the feasibility of scalable bioproduction.

Indexed as

beta-GlucosidaseEscherichia coliGinsenosidesMetabolic EngineeringPanaxRecombinant Proteinsbeta-Glucosidaseginsenoside compound Kginsenoside Rb1GinsenosidesRecombinant Proteinsanti‐agingbioconversioncompound CKginsenoside Rb1recombinant β‑glycosidase

Identifiers

PMID42478317
PMCPMC13576745

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.